Drugs that contain Bempedoic Acid; Ezetimibe
1. Nexlizet patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7335799 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2025
(1 year, 7 months from now) | |
| US11613511 | ESPERION THERAPS INC | Methods of making bempedoic acid and compositions of the same |
Jun, 2040
(16 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8497301 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2023
(4 months ago) | |
| US10941095 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2023
(4 months ago) | |
| US10118881 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2023
(4 months ago) | |
| US9624152 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2023
(4 months ago) | |
| US9000041 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2023
(4 months ago) | |
| US10912751 | ESPERION THERAPS INC | Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease |
Mar, 2036
(11 years from now) | |
| US11744816 | ESPERION THERAPS INC | Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease |
Mar, 2036
(11 years from now) | |
| US11760714 | ESPERION THERAPS INC | Methods of making bempedoic acid and compositions of the same |
Jun, 2040
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 21, 2025 |
| New Product(NP) | Feb 26, 2023 |
NCE-1 date: 22 February, 2024
Market Authorisation Date: 26 February, 2020
Treatment: Use of nexlizet as an adjunct to diet and maximally tolerated statin therapy to lower ldl-c in adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular dise...
Dosage: TABLET;ORAL
More Information on Dosage
NEXLIZET family patents
